Combination of Albumin-Bound Paclitaxel and Cisplatin with Radiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma: Results from a Phase II Single-Arm Study - Scorecard - MDSpire
Advertisement
Combination of Albumin-Bound Paclitaxel and Cisplatin with Radiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma: Results from a Phase II Single-Arm Study
Clinical Scorecard: Combination of Albumin-Bound Paclitaxel and Cisplatin with Radiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma: Results from a Phase II Single-Arm Study
Concurrent chemoradiotherapy combining nab-paclitaxel (a nanoparticle albumin-bound formulation enhancing tissue permeability and radiosensitization) with cisplatin and intensity-modulated radiotherapy
Target Population
Patients aged 18-70 with pathologically confirmed locally advanced unresectable or surgery-unwilling ESCC, no prior antitumour therapy, stable hepatic and renal function
Care Setting
Single-centre oncology clinical trial setting with multidisciplinary management including chemotherapy and radiotherapy
Key Highlights
Nab-paclitaxel combined with cisplatin and radiotherapy was evaluated as a potentially more effective and better-tolerated alternative to standard cisplatin plus 5-fluorouracil regimens.
Phase I dose escalation identified 75 mg/m² nab-paclitaxel weekly with 25 mg/m² cisplatin as the recommended dose for Phase II evaluation.
Treatment involved weekly intravenous infusions of nab-paclitaxel and cisplatin concurrent with intensity-modulated radiotherapy delivering 50-64 Gy in 25-32 fractions.
Guideline-Based Recommendations
Diagnosis
Pathological confirmation of squamous cell carcinoma of the oesophagus.
Clinical staging according to AJCC 8th edition including imaging (CT thorax/abdomen), barium oesophagography, and endoscopic ultrasound.
Management
Concurrent chemoradiotherapy with nab-paclitaxel (75 mg/m²) and cisplatin (25 mg/m²) administered weekly on days 1, 8, 15, 22, and 29.
Intensity-modulated radiotherapy targeting gross tumour volume plus margins, with doses ranging from 50 to 64 Gy in conventional fractionation.
Premedication not required for nab-paclitaxel infusion; adequate hydration to prevent cisplatin nephrotoxicity.
Monitoring & Follow-up
Regular assessment for haematologic and non-haematologic toxicities to determine continuation or withdrawal of chemotherapy.
Monitoring for severe treatment-related adverse events such as oesophageal fistula, haemorrhage, or grade ≥3 respiratory toxicity to guide radiotherapy discontinuation.
Follow-up includes physical examination, laboratory tests, imaging, and endoscopic evaluation.
Risks
Potential for severe haematologic and non-haematologic toxicities necessitating treatment delays or discontinuation.
Risk of oesophageal fistula, haemorrhage, and respiratory toxicities during treatment.
Known toxicities of cisplatin including nephrotoxicity mitigated by hydration.
Patient & Prescribing Data
Adults 18-70 years with locally advanced unresectable or surgery-unwilling ESCC, no prior therapy, adequate organ function, and no distant metastases or contraindications.
Weekly nab-paclitaxel at 75 mg/m² combined with cisplatin 25 mg/m² and concurrent radiotherapy is feasible without premedication, with dose selection guided by Phase I pharmacokinetic and toxicity data.
Clinical Best Practices
Use intensity-modulated radiotherapy with precise target volume delineation including GTV, CTV, and PTV margins.
Administer nab-paclitaxel via 30-minute intravenous infusion without premedication to reduce hypersensitivity risk.
Ensure adequate hydration during cisplatin administration to prevent nephrotoxicity.
Monitor patients closely for toxicities and discontinue chemotherapy if delays exceed two weeks due to adverse events.
Discontinue radiotherapy if severe unresolved treatment-related complications occur.
